Repeated Herbal Acupoint Sticking Relieved the Recurrence of Allergic Asthma by Regulating the Th1Th2 Cell Balance in the Peripheral Blood

الملخص EN

Allergic asthma is an inflammatory disease involving the Th1/Th2 cell imbalance in the peripheral blood.

Repeated herbal acupoint sticking (RHAS) has been used for hundreds of years in China to relieve the recurrence of allergic asthma, and it is still practiced today.

Thus, we explored the effect on allergic asthma relapse and the underlying immunoregulatory mechanism in this study.

Here, we enrolled 50 allergic asthma participants, and 38 of them completed the treatment and follow-up (the allergic asthma group).

In addition, 13 healthy participants (the control group) were enrolled.

The recurrence number of allergic asthma participants and asthma control test (ACT) were used to evaluate the effect of treatment on relieving allergic asthma recurrence.

Flow cytometry was performed to analyze the levels of Th1 and Th2 cells in the peripheral blood.

The serum levels of IgE, IFN-γ, and IL-4 were detected by ELISA.

(1) In the allergic asthma group, compared to before the first treatment, the recurrence number of allergic asthma participants decreased and the ACT score increased at end of the last treatment, 18 and 30 weeks of the trial (P<0.05).

At 18 and 30 weeks of the trial, the recurrence number of allergic asthma participants was less and the ACT score was higher than the ones from the same period last year in the allergic asthma group (P<0.05).

Compared to before the first treatment, the percentage of Th1 cell did not change significantly, the percentage of Th2 cell decreased, and the Th1/Th2 cell ratio increased in the allergic asthma group by the end of the last treatment (P<0.05).

Meanwhile, the release of IgE and IL-4 reduced (P<0.05), and the release of IFN-γ did not significantly change in the allergic asthma group.

(2) Compared with the control group, the serum levels of IgE and IL-4 and the percentage of Th2 cell were higher, and the Th1/Th2 cell ratio was lower in the allergic asthma group (P<0.05).

There was no significant difference between Th1 cell and IFN-γ before the first treatment.

(3) Compared with the control group, the IgE levels and the percentage of Th2 cell were higher in the allergic asthma group (P<0.01).

Simultaneously, there was no significant difference between Th1 cell, the Th1/Th2 cell ratio, and the serum levels of IFN-γ and IL-4 by the end of the last treatment.

The data suggested that RHAS reduced the amount of Th2 cell and elevated the Th1/Th2 cell ratio, thereby alleviating the inflammatory responses in the allergic asthma participants.